NCT00191308 - Molecular Profiling in Lung Cancer Patients | Biotech Hunter

Enrollment

30

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

December 31, 2010

Conditions

Non-Small Cell Lung CancerCarcinoma

Interventions

DRUG

pemetrexed

500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

DRUG

cisplatin

75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

PROCEDURE

Radical Non-Small Cell Lung Cancer (NSCLC) surgery

All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.

Trial Locations (3)

43-360

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bystra

60-569

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan

02-781

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw